BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES

BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES

Deciphering the mechanisms of the pathogenesis of immune-mediated inflammatory rheumatic diseases (IMIRDs) in conjunction with designing a wide range of biological agents is one of the major medical advances in the 21st century. A new promising area of pharmacotherapy for IMIRDs is associated with t...

ver descrição completa

Detalhes bibliográficos
Principais autores:	E. L. Nasonov, A. M. Lila
Formato:	Artigo
Idioma:	Russian
Publicado em:	IMA PRESS LLC 2020-06-01
coleção:	Научно-практическая ревматология
Assuntos:	rheumatoid arthritis janus kinase inhibitors baricitinib
Acesso em linha:	https://rsp.mediar-press.net/rsp/article/view/2898

Registros relacionados

Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis
por: Cristina Martinez-Molina, et al.
Publicado em: (2024-02-01)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
por: Vishal R. Tandon, et al.
Publicado em: (2022-07-01)

Baricitinib: key results of long-term use in rheumatoid arthritis
por: N. V. Chichasova, et al.
Publicado em: (2024-08-01)

Clinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospects
por: V. I. Mazurov, et al.
Publicado em: (2019-10-01)

Cutaneous eruption after commencing baricitinib for rheumatoid arthritis
por: Rosemary Akinbisehin, et al.
Publicado em: (2024-06-01)

A rare case of symptomatic creatine kinase elevation in a patient with rheumatoid arthritis treated with baricitinib
por: F.M. Mariani, et al.
Publicado em: (2024-06-01)

Two pemphigoid cases with mucous membrane involvement successfully treated with baricitinib
por: Tamás Malkovics, et al.
Publicado em: (2024-12-01)

Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis
por: Bong-Woo Lee, et al.
Publicado em: (2024-09-01)

Efficacy and safety of baricitinib in rheumatoid arthritis patients with moderate renal impairment: a multicenter propensity score matching study
por: Akira Maeyama, et al.
Publicado em: (2024-12-01)

Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
por: I. V. Menshikova, et al.
Publicado em: (2019-05-01)

The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases
por: E. L. Nasonov, et al.
Publicado em: (2020-11-01)

Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib
por: A. E. Karateev
Publicado em: (2020-09-01)

Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors
por: A. O. Bobkova, et al.
Publicado em: (2024-08-01)

A new trend in pathogenetic treatment of rheumatoid arthritis: tofacitinib, the first inhibitor of Janus kinase
por: Dmitry Evgenyevich Karateev
Publicado em: (2014-03-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
por: E. L. Nasonov
Publicado em: (2014-06-01)

Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
por: Zoe Apalla, et al.
Publicado em: (2024-04-01)

Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor
por: Ya-Chun Huang, et al.
Publicado em: (2025-02-01)

Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients
por: Simone Parisi, et al.
Publicado em: (2024-01-01)

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
por: Teppei Hagino, et al.
Publicado em: (2023-12-01)

JAK inhibitors attenuate hyperactivation of nonswitched memory B cells in rheumatoid arthritis patients in remission
por: Jing Luo, et al.
Publicado em: (2024-07-01)

Epigenetic targets of Janus kinase inhibitors are linked to genetic risks of rheumatoid arthritis
por: Haruka Tsuchiya, et al.
Publicado em: (2024-06-01)

Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics
por: Oh Chan Kwon, et al.
Publicado em: (2024-04-01)

RETRACTED: Baricitinib protects mice from sepsis-induced cardiac dysfunction and multiple-organ failure
por: Chiara Verra, et al.
Publicado em: (2023-09-01)

Treatment of rheumatoid arthritis with baricitinib or upadacitinib is associated with reduced scaffold protein NEDD9 levels in CD4+ T cells
por: Viktoria Golumba‐Nagy, et al.
Publicado em: (2023-10-01)

Non-Invasive Assessment of Micro- and Macrovascular Function after Initiation of JAK Inhibitors in Patients with Rheumatoid Arthritis
por: Panagiota Anyfanti, et al.
Publicado em: (2024-04-01)

Baricitinib improves pulmonary fibrosis in mice with rheumatoid arthritis-associated interstitial lung disease by inhibiting the Jak2/Stat3 signaling pathway
por: Hongli Liu, et al.
Publicado em: (2023-08-01)

Treatment with tofacitinib attenuates muscle loss through myogenin activation in the collagen-induced arthritis
por: Thales Hein da Rosa, et al.
Publicado em: (2024-11-01)

Patients with High Baseline Neutrophil-to-Lymphocyte Ratio Exhibit Better Response to Filgotinib as Treatment for Rheumatoid Arthritis
por: Peter C. Taylor, et al.
Publicado em: (2024-07-01)

Case report: Effectiveness of Janus kinase inhibitors in the management of isolated noninfectious uveitis: a case series
por: Nina Vidic Krhlikar, et al.
Publicado em: (2025-03-01)

Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis
por: Grace Xiong, BHSc, et al.
Publicado em: (2025-04-01)

Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
por: Alexander Egeberg, et al.
Publicado em: (2023-10-01)

Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)
por: E. L. Nasonov, et al.
Publicado em: (2020-02-01)

PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS: NEW STRATEGY, NEW TARGETS
por: E. L. Nasonov
Publicado em: (2017-09-01)

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study
por: Peter C. Taylor, et al.
Publicado em: (2024-12-01)

Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study
por: Louis Bessette, et al.
Publicado em: (2024-03-01)

Atypical clinical presentation of rheumatoid arthritis
por: Bošković Ksenija, et al.
Publicado em: (2023-01-01)

Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary
por: Peter C. Taylor, et al.
Publicado em: (2024-10-01)

Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data
por: Hong Ki Min, et al.
Publicado em: (2023-04-01)

Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: An evidence-based review
por: Siddhartha Sood, HBSc, et al.
Publicado em: (2024-09-01)

Successful Therapy of Severe and Refractory Cutaneous Sarcoidosis with Baricitinib
por: Giuseppe Russo, et al.
Publicado em: (2024-04-01)